Effect of extended-release niacin on new-onset diabetes among hyperlipidemic patients treated with ezetimibe/simvastatin in a randomized controlled trial

John R. Guyton, Sergio Fazio, Adeniyi J. Adewale, Erin Jensen, Joanne E. Tomassini, Arvind Shah, Andrew M. Tershakovec

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

OBJECTIVE - To determine the effect of niacin on fasting glucose (FG) and new-onset diabetes in statin/ezetimibe-treated patients. RESEARCH DESIGN AND METHODS - This was a prespecified secondary analysis among 942 hyperlipidemic patients randomized to ezetimibe/simvastatin (E/S; 10/20 mg) or E/S + extended-release niacin (N; titrated to 2 g) over 64 weeks. RESULTS - FG levels peaked by 8-12 weeks, then declined even without antidiabetic medication. At 64 weeks, 3.5% taking E/S+N versus 2.6% taking E/S met criteria for new-onset diabetes (P = 0.66). An additional 1.4% taking E/S+N versus 0.4% taking E/S transiently met criteria for diabetes and then remitted (P = 0.46). Of 28 new-diabetes diagnoses in the E/S+N group, 25 occurred by 24 weeks. Among patientswith baseline diabetes, 13.9%taking E/S+N and 11.6% taking E/S underwent antidiabetic treatment modification. CONCLUSIONS - Increased FG and new-onset diabeteswith E/S+N occurred mainly around the time of initial uptitration of N and often improved or remitted without specific treatment.

Original languageEnglish (US)
Pages (from-to)857-860
Number of pages4
JournalDiabetes Care
Volume35
Issue number4
DOIs
StatePublished - Apr 2012
Externally publishedYes

Fingerprint

Simvastatin
Niacin
Fasting
Randomized Controlled Trials
Hypoglycemic Agents
Glucose
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Research Design
Therapeutics
Ezetimibe

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism
  • Advanced and Specialized Nursing

Cite this

Effect of extended-release niacin on new-onset diabetes among hyperlipidemic patients treated with ezetimibe/simvastatin in a randomized controlled trial. / Guyton, John R.; Fazio, Sergio; Adewale, Adeniyi J.; Jensen, Erin; Tomassini, Joanne E.; Shah, Arvind; Tershakovec, Andrew M.

In: Diabetes Care, Vol. 35, No. 4, 04.2012, p. 857-860.

Research output: Contribution to journalArticle

Guyton, John R. ; Fazio, Sergio ; Adewale, Adeniyi J. ; Jensen, Erin ; Tomassini, Joanne E. ; Shah, Arvind ; Tershakovec, Andrew M. / Effect of extended-release niacin on new-onset diabetes among hyperlipidemic patients treated with ezetimibe/simvastatin in a randomized controlled trial. In: Diabetes Care. 2012 ; Vol. 35, No. 4. pp. 857-860.
@article{2bc40fa2f4e6411289ed58e0aec0b06f,
title = "Effect of extended-release niacin on new-onset diabetes among hyperlipidemic patients treated with ezetimibe/simvastatin in a randomized controlled trial",
abstract = "OBJECTIVE - To determine the effect of niacin on fasting glucose (FG) and new-onset diabetes in statin/ezetimibe-treated patients. RESEARCH DESIGN AND METHODS - This was a prespecified secondary analysis among 942 hyperlipidemic patients randomized to ezetimibe/simvastatin (E/S; 10/20 mg) or E/S + extended-release niacin (N; titrated to 2 g) over 64 weeks. RESULTS - FG levels peaked by 8-12 weeks, then declined even without antidiabetic medication. At 64 weeks, 3.5{\%} taking E/S+N versus 2.6{\%} taking E/S met criteria for new-onset diabetes (P = 0.66). An additional 1.4{\%} taking E/S+N versus 0.4{\%} taking E/S transiently met criteria for diabetes and then remitted (P = 0.46). Of 28 new-diabetes diagnoses in the E/S+N group, 25 occurred by 24 weeks. Among patientswith baseline diabetes, 13.9{\%}taking E/S+N and 11.6{\%} taking E/S underwent antidiabetic treatment modification. CONCLUSIONS - Increased FG and new-onset diabeteswith E/S+N occurred mainly around the time of initial uptitration of N and often improved or remitted without specific treatment.",
author = "Guyton, {John R.} and Sergio Fazio and Adewale, {Adeniyi J.} and Erin Jensen and Tomassini, {Joanne E.} and Arvind Shah and Tershakovec, {Andrew M.}",
year = "2012",
month = "4",
doi = "10.2337/dc11-1369",
language = "English (US)",
volume = "35",
pages = "857--860",
journal = "Diabetes Care",
issn = "1935-5548",
publisher = "American Diabetes Association Inc.",
number = "4",

}

TY - JOUR

T1 - Effect of extended-release niacin on new-onset diabetes among hyperlipidemic patients treated with ezetimibe/simvastatin in a randomized controlled trial

AU - Guyton, John R.

AU - Fazio, Sergio

AU - Adewale, Adeniyi J.

AU - Jensen, Erin

AU - Tomassini, Joanne E.

AU - Shah, Arvind

AU - Tershakovec, Andrew M.

PY - 2012/4

Y1 - 2012/4

N2 - OBJECTIVE - To determine the effect of niacin on fasting glucose (FG) and new-onset diabetes in statin/ezetimibe-treated patients. RESEARCH DESIGN AND METHODS - This was a prespecified secondary analysis among 942 hyperlipidemic patients randomized to ezetimibe/simvastatin (E/S; 10/20 mg) or E/S + extended-release niacin (N; titrated to 2 g) over 64 weeks. RESULTS - FG levels peaked by 8-12 weeks, then declined even without antidiabetic medication. At 64 weeks, 3.5% taking E/S+N versus 2.6% taking E/S met criteria for new-onset diabetes (P = 0.66). An additional 1.4% taking E/S+N versus 0.4% taking E/S transiently met criteria for diabetes and then remitted (P = 0.46). Of 28 new-diabetes diagnoses in the E/S+N group, 25 occurred by 24 weeks. Among patientswith baseline diabetes, 13.9%taking E/S+N and 11.6% taking E/S underwent antidiabetic treatment modification. CONCLUSIONS - Increased FG and new-onset diabeteswith E/S+N occurred mainly around the time of initial uptitration of N and often improved or remitted without specific treatment.

AB - OBJECTIVE - To determine the effect of niacin on fasting glucose (FG) and new-onset diabetes in statin/ezetimibe-treated patients. RESEARCH DESIGN AND METHODS - This was a prespecified secondary analysis among 942 hyperlipidemic patients randomized to ezetimibe/simvastatin (E/S; 10/20 mg) or E/S + extended-release niacin (N; titrated to 2 g) over 64 weeks. RESULTS - FG levels peaked by 8-12 weeks, then declined even without antidiabetic medication. At 64 weeks, 3.5% taking E/S+N versus 2.6% taking E/S met criteria for new-onset diabetes (P = 0.66). An additional 1.4% taking E/S+N versus 0.4% taking E/S transiently met criteria for diabetes and then remitted (P = 0.46). Of 28 new-diabetes diagnoses in the E/S+N group, 25 occurred by 24 weeks. Among patientswith baseline diabetes, 13.9%taking E/S+N and 11.6% taking E/S underwent antidiabetic treatment modification. CONCLUSIONS - Increased FG and new-onset diabeteswith E/S+N occurred mainly around the time of initial uptitration of N and often improved or remitted without specific treatment.

UR - http://www.scopus.com/inward/record.url?scp=84862107330&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84862107330&partnerID=8YFLogxK

U2 - 10.2337/dc11-1369

DO - 10.2337/dc11-1369

M3 - Article

C2 - 22338103

AN - SCOPUS:84862107330

VL - 35

SP - 857

EP - 860

JO - Diabetes Care

JF - Diabetes Care

SN - 1935-5548

IS - 4

ER -